Cover Image

An empirical survey on the adaption of neoadjuvant chemotherapy in bladder cancer

Introduction: The aim of the study was to determine the adaption of neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC) in Germany, Austria, and Switzerland and especially underlying reasons for potential low adherence to guidelines. Methods: We conducted a non-vali...

Full description

Saved in:
Bibliographic Details
Main Authors: Reike, Moritz (Author) , Reicherz, Alina (Author) , Tully, Karl H. (Author) , Bahlburg, Henning (Author) , Maas, Moritz (Author) , Bach, Peter (Author) , Klümper, Niklas (Author) , Eckstein, Markus (Author) , Hartmann, Arndt (Author) , Breyer, Johannes (Author) , Erben, Philipp (Author) , Bolenz, Christian (Author) , Noldus, Joachim (Author) , Berg, Sebastian (Author) , Roghmann, Florian (Author)
Format: Article (Journal)
Language:English
Published: June 2024
In: Urologia internationalis
Year: 2024, Volume: 108, Issue: 3, Pages: 183-189
ISSN:1423-0399
DOI:10.1159/000536321
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000536321
Verlag, lizenzpflichtig, Volltext: https://karger.com/uin/article-abstract/108/3/183/894478/An-Empirical-Survey-on-the-Adaption-of-Neoadjuvant?redirectedFrom=fulltext
Get full text
Author Notes:Moritz J. Reike, Alina Reicherz, Karl H. Tully, Henning Bahlburg, Moritz Maas, Peter Bach, Niklas Klümper, Markus Eckstein, Arndt Hartmann, Johannes Breyer, Philipp Erben, Christian Bolenz, Joachim Noldus, Sebastian Berg, Florian Roghmann
Description
Summary:Introduction: The aim of the study was to determine the adaption of neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC) in Germany, Austria, and Switzerland and especially underlying reasons for potential low adherence to guidelines. Methods: We conducted a non-validated survey among 336 urologic departments in Germany, Austria, and Switzerland. RedCap questionnaires were electronically distributed and included 23 items concerning the general NAC administration standards and guideline compliance in patient counseling regarding the actual treatment. Results: The return rate of the questionnaire was 19.1% (63/336). Although 45 departments (71.4%) claim to perform NAC as the standard of care, only 49% of eligible patients actually receive NAC. An advanced disease stage (≥cT3) and a high tumor volume were mentioned to support the application of NAC, whereas 35% of responders worry about deterioration of patients’ preoperative status due to NAC. Furthermore, 26.7% of respondents are concerned about the low extent of survival benefit. Conclusion: Application of NAC in eligible MIBC patients in Germany, Austria, and Switzerland remains low. Although the majority of urologic departments discuss NAC and acknowledge the need for intensified treatment in advanced disease stages, not all eligible patients will actually receive NAC before radical cystectomy.
Item Description:Online veröffentlich: 19. Januar 2024
Gesehen am 22.01.2025
Physical Description:Online Resource
ISSN:1423-0399
DOI:10.1159/000536321

Similar Items